The Effect of Neuropsychiatric Drugs on the Oxidation-Reduction Balance in Therapy
International Journal of Molecular Sciences · 03.07.2024 · 25 (13) · 7304
DOI: 10.3390/ijms25137304 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 03.07.2024. Verfasst von Karina Sommerfeld-Klatta und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Toxicology, Poznań University of Medical Sciences, 3 Rokietnicka Street, 60-806 Poznań, Poland. Hauptthemen laut MEDLINE: Oxidation-Reduction, Oxidative Stress, Antipsychotic Agents, Antidepressive Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 200 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The effectiveness of available neuropsychiatric drugs in the era of an increasing number of patients is not sufficient, and the complexity of neuropsychiatric disease entities that are difficult to diagnose and therapeutically is increasing. Also, discoveries about the pathophysiology of neuropsychiatric diseases are promising, including those initiating a new round of innovations in the role of oxidative stress in the etiology of neuropsychiatric diseases. Oxidative stress is highly related to mental disorders, in the treatment of which the most frequently used are first- and second-generation antipsychotics, mood stabilizers, and antidepressants. Literature reports on the effect of neuropsychiatric drugs on oxidative stress are divergent. They are starting with those proving their protective effect and ending with those confirming disturbances in the oxidation–reduction balance. The presented publication reviews the state of knowledge on the role of oxidative stress in the most frequently used therapies for neuropsychiatric diseases using first- and second-generation antipsychotic drugs, i.e., haloperidol, clozapine, risperidone, olanzapine, quetiapine, or aripiprazole, mood stabilizers: lithium, carbamazepine, valproic acid, oxcarbazepine, and antidepressants: citalopram, sertraline, and venlafaxine, along with a brief pharmacological characteristic, preclinical and clinical studies effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Toxicology, Poznań University of Medical Sciences, 3 Rokietnicka Street, 60-806 Poznań, Poland.
- Department of Forensic Medicine, Poznań University of Medical Sciences, 10 Rokietnicka Street, 60-806 Poznań, Poland.
- Department of Emergency Medicine, Poznań University of Medical Sciences, 7 Rokietnicka Street, 60-806 Poznań, Poland.
ORCID-Profile: Karina Sommerfeld-Klatta, Szymon Rzepczyk, Filip Nowicki
Zitieren
APA
Sommerfeld-Klatta, K., Jiers, W., Rzepczyk, S., Nowicki, F., Łukasik-Głębocka, M., Świderski, P., Zielińska-Psuja, B., Żaba, Z., & Żaba, C. (2024). The Effect of Neuropsychiatric Drugs on the Oxidation-Reduction Balance in Therapy. International Journal of Molecular Sciences, 25(13), 7304. https://doi.org/10.3390/ijms25137304
Vancouver
Sommerfeld-Klatta K, Jiers W, Rzepczyk S, Nowicki F, Łukasik-Głębocka M, Świderski P, et al. The Effect of Neuropsychiatric Drugs on the Oxidation-Reduction Balance in Therapy. International Journal of Molecular Sciences. 2024;25(13):7304. doi:10.3390/ijms25137304
BibTeX
@article{SommerfeldKlatta2024,
author = {Sommerfeld-Klatta, Karina and Jiers, Wiktoria and Rzepczyk, Szymon and Nowicki, Filip and Łukasik-Głębocka, Magdalena and Świderski, Paweł and Zielińska-Psuja, Barbara and Żaba, Zbigniew and Żaba, Czesław},
title = {The Effect of Neuropsychiatric Drugs on the Oxidation-Reduction Balance in Therapy},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {13},
pages = {7304},
doi = {10.3390/ijms25137304}
}
EUVIMED